Abstract

Interventions in the human germline have been regarded as a red line in genetic engineering up to now. However, with the recent progress in genome editing techniques, first and foremost CRISPR-based methods, the tide seems to be turning. The therapeutic benefits in particular are brought forward as an argument in favor of germline genome editing. According to this view, the main benefit of GGE is disease prevention. The procedure could be used to prevent monogenetic conditions for which no treatment is available so far. This leads many commentators to the view that the benefits of GGE outweigh the risks. In this article, I examine the status and ethical implications of GGE as a means of disease prevention. I intend to show that the notion of GGE as disease prevention is only true for one specific application. Instead of being preventive treatments, most applications of GGE are advanced techniques of assisted reproduction. As such, they can be thought of as wish-fulfilling medicine, that is the use of medical techniques for non-medically indicated purposes. Thus, it is necessary to reconsider the risk-benefit analysis of GGE for most of its applications.